How effective is entrectinib in the treatment of solid tumors?

Entrectinib is a targeted therapy drug that is widely used to treat a variety of solid tumors, including tumors carrying NTRK gene fusion mutations and ROS1, ALK and other gene mutations. Through data analysis from multiple clinical trials, we can gain a comprehensive understanding of the efficacy and safety of entrectinib in the treatment of solid tumors.

1.Clinical trial review: Clinical trials of entrectinib cover a variety of solid tumor types, the most representative of which isSTARTRK-2(Study of Tumor-Agnostic Therapy With Entrectinib in Subjects With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements) experiment. This trial includes a multicenter, open-label study designed to evaluate the efficacy and safety of entrectinib in a variety of solid tumors harboring specific genetic mutations.

2.Overall response rate (ORR): STARTRK-2In the trial, the patient's overall response rate is an important clinical endpoint, which reflects the patient's overall clinical response to treatment. The overall response rate to entrectinib was approximately 57.4% in all patients with solid tumors harboring NTRK, ROS1, or ALK gene fusion mutations. This suggests that the majority of patients showed a positive clinical response to entrectinib.

3.Duration of response (DOR): For those patients who show a response to entrectinib, duration of response is an important metric that reflects the duration of the treatment effect. In the STARTRK-2 trial, the median duration of response was more than two years, suggesting that entrectinib can provide durable benefits for some patients.

4.Progression-free survival time (PFS): Progression-free survival time is one of the key indicators to evaluate the effect of treatment. It reflects the time it takes for a patient's disease to progress after receiving treatment. In the STARTRK-2 trial, the median progression-free survival time for all patients with solid tumors harboring NTRK, ROS1, or ALK gene fusion mutations was approximately 11.2 months.

5.Safety: In theSTARTRK-2 trial, entrectinib showed relatively good safety and tolerability. Common adverse reactions include fatigue, nausea, vomiting, visual disturbances, and abnormal liver function. However, these adverse reactions are usually mild to moderate and rarely lead to treatment interruption or discontinuation.

Taken together, entrectinib, as a targeted therapy for a variety of solid tumors, has demonstrated significant efficacy and relatively good safety in clinical trials. Most patients show positive clinical responses to the drug, with long-lasting responses and prolonged progression-free survival. Although some patients may experience some adverse effects, these are usually manageable. Therefore, entrectinib has broad clinical application prospects in the treatment of solid tumors harboring specific genetic mutations and provides an effective treatment option for this patient population.